Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Jarrod Longcor, Kate Oliver, BS

Blood (2019) 134 (Supplement_1): 1864.

https://doi.org/10.1182/blood-2019-131806

Published: 2019

Journal Articles

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Janice M Spence, PhD, Diana Adlowitz, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 919.

https://doi.org/10.1182/blood-2018-99-111399

Published: 2018

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

Journal Articles

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Paul M. Barr, Hongli Li, PhD, Richard Burack, MD PhD, Michael LeBlanc, PhD, Sonali M. Smith, MD, Ajay K. Gopal, MD, Justin D. Floyd, DO, Daniel O. Persky, MD, Oliver Press, MD PhD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2016) 128 (22): 614.

https://doi.org/10.1182/blood.V128.22.614.614

Published: 2016

Journal Articles

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paul S Martin, MD, Isaac C Jenkins, MS, Theodore A Gooley, PhD, Damian J Green, MD, John M Pagel, MD PhD, Sally J Lundberg, RN, Lacey M Hedine, Joseph G Rajendran, MD, Andrew T Shields, MD, Darrell R Fisher, PhD, David G Maloney, MD PhD, Frederick R Appelbaum, MD, Ryan D Cassaday, MD, Oliver W Press, MD PhD, Ajay K. Gopal, MD

Blood (2015) 126 (23): 5502.

https://doi.org/10.1182/blood.V126.23.5502.5502

Published: 2015

Journal Articles

Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma

Patrick M. Reagan, MD, Jennifer L. Kelly, PhD MPH, Andrea Baran, MS, Paul M. Barr, MD, Carla Casulo, MD, Vaseem Chengazi, MD PhD, Jonathan W. Friedberg, MD MMSc

Blood (2014) 124 (21): 1746.

https://doi.org/10.1182/blood.V124.21.1746.1746

Published: 2014

Journal Articles

Early Occurrence of Therapy-Related Acute Myeloid Leukemia (t-AML) with Monocytic Differentiation with Trisomy 8 Cytogenetic Abnormality after Radioactive Iodine (RAI) Treatment for Papillary Thyroid Cancer

Oscar Boutros Lahoud, MD, Dhakal Ajay, MD, Abhinav B Chandra, MD

Blood (2014) 124 (21): 5325.

https://doi.org/10.1182/blood.V124.21.5325.5325

Published: 2014

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

Journal Articles

A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Ryan D. Cassaday, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Joseph G. Rajendran, MD, Theodore A. Gooley, PhD, Darrell R. Fisher, PhD, Sally J. Lundberg, Lacey M. Hedin, Andrew T. Shields, MD, Damian J. Green, MD, Robert S. Miyaoka, PhD, Frederick R. Appelbaum, MD, Ajay K. Gopal, MD

Blood (2013) 122 (21): 3333.

https://doi.org/10.1182/blood.V122.21.3333.3333

Published: 2013

Journal Articles

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Daniel Lebovic, MD, Mark S. Kaminski, MD, Tara B. Anderson, Kristen Detweiler-Short, Kent A. Griffith, Terri L. Jobkar, BSN, Malathi Kandarpa, PhD, Andrzej Jakubowiak, MD, PhD

Blood (2012) 120 (21): 1854.

https://doi.org/10.1182/blood.V120.21.1854.1854

Published: 2012

Journal Articles

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Ajay K. Gopal, MD, Ted A. Gooley, PhD, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2012) 120 (21): 811.

https://doi.org/10.1182/blood.V120.21.811.811

Published: 2012

Journal Articles

Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.

Jennifer L. Kelly, PhD, MPH, Gilles Salles, MD, Bryan H. Goldman, MS, Richard I Fisher, MD, Olivier Casasnovas, Oliver W. Press, MD, PhD, David G. Maloney, MD, PhD, Pierre Soubeyran, Lisa M. Rimsza, MD, Michael LeBlanc, PhD, Herve Tilly, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2712.

https://doi.org/10.1182/blood.V120.21.2712.2712

Published: 2012

Journal Articles

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Ajay K. Gopal, MD, Ted Gooley, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 663.

https://doi.org/10.1182/blood.V118.21.663.663

Published: 2011

Journal Articles

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Oliver W. Press, MD, PhD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Jonathan Friedberg, MD, Michael LeBlanc, Ph.D., Myron S. Czuczman, MD, Mark S. Kaminski, MD, Rita M. Braziel, MD, David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2011) 118 (21): 98.

https://doi.org/10.1182/blood.V118.21.98.98

Published: 2011

Journal Articles

A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL)

Adam C. Rose, Gia Garrett, Miray Seward, Pareen J Shenoy, MBBS, MPH, Roy A Kucuk, Hannah Doksansky, Christopher R Flowers, MD

Blood (2011) 118 (21): 101.

https://doi.org/10.1182/blood.V118.21.101.101

Published: 2011

Journal Articles

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Julie M Vose, MD, Shelly L Carter, ScD, Linda J Burns, MD, Ernesto Ayala, MD, Oliver W. Press, MD, PhD, Craig H. Moskowitz, MD, Edward A. Stadtmauer, MD, Shin Mineishi, MD, Richard F. Ambinder, Timothy S. Fenske, MD, Mary M. Horowitz, MD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 661.

https://doi.org/10.1182/blood.V118.21.661.661

Published: 2011

Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC

Blood (2010) 116 (21): 4916.

https://doi.org/10.1182/blood.V116.21.4916.4916

Published: 2010

Journal Articles

Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.

Peter Martin, FRCPC, MD, MS, Morton Coleman, MD, Richard R. Furman, MD, Shankar Vallabhajosula, Dong Sun Kim, Andrew Edelstein, Julia Morrison, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Stanley J. Goldsmith, John P. Leonard, MD

Blood (2010) 116 (21): 1785.

https://doi.org/10.1182/blood.V116.21.1785.1785

Published: 2010

Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose

Blood (2010) 116 (21): 3960.

https://doi.org/10.1182/blood.V116.21.3960.3960

Published: 2010

NARROW

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma

Early Occurrence of Therapy-Related Acute Myeloid Leukemia (t-AML) with Monocytic Differentiation with Trisomy 8 Cytogenetic Abnormality after Radioactive Iodine (RAI) Treatment for Papillary Thyroid Cancer

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL)

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only